Clinical Trial Update: RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating everolimus (RAD001) in relapsed or refractory hematologic malignancies, including leukemia, mantle cell lymphoma, and mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Mantle Cell Lymphoma
• Myelofibrosis

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED